News
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...
After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...
Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...
Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...
Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...
Zacks.com on MSN20h
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...
Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback